Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Heidelberg Pharma AGWBO:HPHA 32 Net Current Asset Value is €-0.50 as of May. 2026. GuruFocus rates WBO:HPHA with a GF Score™ of 32/100 and a GF Value™ of €2.87 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 941 Biotechnology companies, Heidelberg Pharma AG ranks worse than 106269.82% on this metric.
In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).
Heidelberg Pharma AG's net current asset value per share for the quarter that ended in May. 2026 was €-0.50.
The historical rank and industry rank for Heidelberg Pharma AG's Net Current Asset Value or its related term are showing as below:
During the past 13 years, the highest Price-to-Net-Current-Asset-Value Ratio of Heidelberg Pharma AG was 228.00. The lowest was 2.29. And the median was 6.32.
WBO:HPHA's Price-to-Net-Current-Asset-Value is not ranked *
in the Biotechnology industry.
Industry Median: 4.98 * Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
Heidelberg Pharma AG (WBO:HPHA) Net Current Asset Value Explanation
Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."
The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]
Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Grahams strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.
Heidelberg Pharma AG Net Current Asset Value Related Terms
Heidelberg Pharma AG Net Current Asset Value Historical Data
* Premium members only.
The historical data trend for Heidelberg Pharma AG's Net Current Asset Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Heidelberg Pharma AG Net Current Asset Value Chart
WBO:HPHA vs VRTX, REGN, ALNY: Net Current Asset Value Comparison
For the Biotechnology subindustry, Heidelberg Pharma AG's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Heidelberg Pharma AG Price-to-Net-Current-Asset-Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Heidelberg Pharma AG's Price-to-Net-Current-Asset-Value distribution charts can be found below:
* The bar in red indicates where Heidelberg Pharma AG's Price-to-Net-Current-Asset-Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Net Current Asset Value of €-0.50 mean?
Heidelberg Pharma AG (WBO:HPHA) has a Net Current Asset Value of €-0.50 as of May. 2026. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Heidelberg Pharma AG and its competitors. Over the past decade, Heidelberg Pharma AG's Net Current Asset Value has ranged from 2.29 to 228.00. According to the industry distribution chart, Heidelberg Pharma AG ranks #999999 out of 941 companies in the Biotechnology industry.
Is Heidelberg Pharma AG's Net Current Asset Value too high?
Heidelberg Pharma AG's current Net Current Asset Value is €-0.50. Over the past 10 years, this metric has ranged from a low of 2.29 to a high of 228.00. Based on the distribution chart, Heidelberg Pharma AG ranks #999999 out of 941 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Heidelberg Pharma AG has a GF Score™ of 32/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Heidelberg Pharma AG's Net Current Asset Value compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Heidelberg Pharma AG ranks #999999 out of 941 companies for Net Current Asset Value. This places Heidelberg Pharma AG in the lower half of its industry. The industry median Net Current Asset Value is 4.98. Historically, Heidelberg Pharma AG's own Net Current Asset Value has ranged from 2.29 to 228.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Current Asset Value for a Biotechnology company?
The median Net Current Asset Value among Biotechnology companies is 4.98, based on 941 companies in the industry. Companies in the top quartile (top 25%) have a Net Current Asset Value significantly above this median, while those in the bottom quartile fall well below. However, Net Current Asset Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Current Asset Value mean?
A high Net Current Asset Value can signal that a stock is expensive relative to its fundamentals. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Heidelberg Pharma AG and its competitors. For the Biotechnology industry, the median Net Current Asset Value is 4.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Heidelberg Pharma AG's current Net Current Asset Value is €-0.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Heidelberg Pharma AG stock overvalued right now?
Based on GuruFocus' analysis, Heidelberg Pharma AG (WBO:HPHA) is currently considered Modestly Undervalued. The stock's GF Value™ is €2.87, compared to a current price of €2.55 — trading 11.1% below its estimated fair value. The current Net Current Asset Value is €-0.50. Heidelberg Pharma AG's overall GF Score™ is 32/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Current Asset Value calculated?
Net Current Asset Value is calculated from a company's financial statements. For Heidelberg Pharma AG (WBO:HPHA), the current Net Current Asset Value is €-0.50 as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Heidelberg Pharma AG (WBO:HPHA) Overvalued in 2026?
Based on GuruFocus' analysis, Heidelberg Pharma AG stock appears to be undervalued.
The current stock price of €2.55 is trading 11.1% below its estimated GF Value™ of €2.87.
GuruFocus considers Heidelberg Pharma AG to be Modestly Undervalued.
Key valuation signals for WBO:HPHA:
Net Current Asset Value: €-0.50
GF Value™: €2.87 vs. price of €2.55 (11.1% below fair value)
No single metric tells the full story. See the WBO:HPHA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Heidelberg Pharma AG is a biopharmaceutical company developing oncology treatments through antibody drug conjugates (ADCs), which combine antibody specificity with toxin potency to selectively target and kill cancer cells. The Company researches, develops, and produces these ADCs, and has built an ADC toolbox using various antibodies and payloads to address multiple cancers and overcome tumor resistance. Its activities focus on its proprietary ATAC technology based on Amanitin, the toxin of the death cap mushroom, leveraging its biological mechanism as a novel cancer therapy. The ATAC platform is used to develop proprietary ADC candidates and is also applied in collaborations with third parties.
32GF Score
Get the complete analysis for WBO:HPHA
Net Current Asset Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WBO:HPHA has been successfully added to your 
